[en] The similarities between patients with untreated growth hormone (GH) deficiency and those with the cardiometabolic syndrome and the beneficial effects of recombinant human GH (rhGH) on body composition have led to the hypothesis that rhGH treatment may have utility in obesity. GH release is reduced in the setting of obesity, primarily due to hyperinsulinism and increased free fatty acid levels. We reviewed the outcomes of 23 clinical studies carried out between 1987 and 2006 that examined the effects of rhGH administration in the obese state. Typically, changes in overall body weight do not occur with rhGH therapy; however, assessment of body composition demonstrates reductions in visceral abdominal fat. Data on the effects of rhGH on lipid and carbohydrate metabolic profiles in obese patients are less clear-cut, with a subset of studies showing a beneficial effect and others a neutral effect. Given the increasing burden of obesity in the general population and the current paucity of effective therapies, it is useful to consider the data on rhGH and obesity from a clinical perspective to highlight potential treatment strategies that harness the somatotropic axis.
Disciplines :
Endocrinology, metabolism & nutrition
Author, co-author :
Rixhon, M.
Tikhomirova, M. A.
Tamagno, G.
Daly, Adrian ; Université de Liège - ULiège > Département des sciences cliniques > Endocrinologie
Beckers, Albert ; Université de Liège - ULiège > Département des sciences cliniques > Endocrinologie
Language :
English
Title :
Current and future perspectives on Recombinant GH for the treatment of Obesity
Lange KH. Fat metabolism in exercise - with special reference to training and growth hormone administration. Scand. J. Med. Sci. Sports 14, 74-99 (2004).
Richelsen B. Action of growth hormone in adipose tissue. Horm. Res. 48(Suppl. 5), 105-110 (1997).
Marcus C, Bolme P, Micha-Johansson G, Margery V, Bronnegard M. Growth hormone increases the lipolytic sensitivity for catecholamines in adipocytes from healthy aduits. Life Sci. 54, 1335-1341 (1994).
Harant I, Beauville M, Crampes F et al. Response of fat cells to growth hormond (GH): effect of long term treatment with recombinant human GH in GH-deficient adults. J Clin. Endocrina. Metab. 78, 1392-1395 (1994).
Wabitsch M, Braun S, Hauner H et al. Mitogenic and antiadipogenic properties of human growth hormone in differentiating human adipocyte precursor cells in primary culture. Pediatr. Res. 40, 450-456 (1996).
Ottosson M, Lonnroth P, Bjorntorp P, Eden S. Effects of cortisol and growth hormone on lipolysis in human adipose tissue. J Clin. Endocrinol. Metab. 85, 799-803 (2000).
Fisker S, Hansen B, Fugisang J et al. Gene expression of the GH receptor in subcutaneous and intraabdominal fat in healthy females: relationship to GH-binding protein. Eur. J. Endocrinol. 150, 773-777 (2004).
Asada N, Takahashi Y, Wada M et al. GH induced lipolysis stimulation in 3T3-L1 adipocytes stably expressing hGHR: analysis on signaling pathway and activity of 20K hGH. Mol. Cell. Endocrinol. 162, 121-129 (2000).
Fleenor D, Arumugarn R, Freemark M. Growth hormone and prolactin receptors in adipogenesis: STAT-5 activation, suppressors of cytokine signaling, and regulation of insulin-like growth factor I. Horm. Res. 66, 101-110 (2006).
Heffernan M, Summers RJ, Thorburn A et al. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and,8(3)-ARknock-out mice. Endocrinology 142, 5182-5189 (2001).
Fain JN, Ihle JH, Bahouth SW. Stimulation of lipolysis but not of leptin release by growth hormone is abolished in adipose tissue from Stat5a and b knockout mice. Biochem. Biophys. Res. Commun. 263, 201-205 (1999).
Jorgensen JOL, Jessen N, Pedersen SB et al. GH receptor signaling in skeletal muscle and adipose tissue in human subjects following exposure to an intravenous GH bolus. Am. J. Physiol. Endocrinol. Metab. 291, E899-E905 (2006).
Shadid S, Jensen MD. Effects of growth hormone administration in human obesity. Obes. Res. 11, 170-175 (2003).
Takano A, Haruta T, Iwata M et al. Growth hormone induces cellular insulin resistance by uncoupling phosphatidylinositol 3-kinase and its downstream signals in 3T3-L1 adipocytes. Diabetes 50, 1891-1900 (2001).
Berryman DE, List EO, Kohn DT, Coschigano KT, Seeley RJ, Kopchick JJ. Effect of growth hormone on susceptibility to diet-induced obesity. Endocrinology 147, 2801-2808 (2006).
Egecioglu E, Bjursell M, Ljungberg A et al. Growth hormone receptor deficiency results in blunted ghrelin feeding response, obesity, and hypolipidemia in mice. Am. J. Physiol. Endocrinol. Metab. 290, E317-E325 (2006).
Hussain MA, Schmitz O, Mengel A et al. Comparison of the effects of growth hormone and insulin-like growth factor I on substrate oxidation and on insulin sensitivity in growth hormone-deficient humans. J. Clin. Invest. 94, 1126-1133 (1994).
Mauras N, O'Brien KO, Welch S et al. Insulin-like growth factor I and growth hormone (GH) treatment in GH-deficient humans: differential effects on protein, glucose, lipid, and calcium metabolism. J. Clin. Endocrinol. Metab. 85, 1686-1694 (2000).
Luque RM, Kineman RD. Impact of obesity on the growth hormone aids: evidence for a direct inhibitory effect of hyperinsulinemia on pituitary function. Endocrinology 147, 2754-2763 (2006).
Eden EB, Burman P, Holdstock C, Ohrvall M, Sundbom M, Karisson FA. Effects of gastric bypass on the GH/IGF-I axis in severe obesity - and a comparison with GH deficiency. Eur. J. Endocrinol. 154, 53-59 (2006).
Ram E, Vishne T, Diker D et al. Impact of gastric banding on plasma ghrelin, growth hormone, cortisol, DHEA and DHEA-S levels. Obes. Surg. 15, 1118-1123 (2005).
Maccario M, Tassone F, Gianotti L et al. Effects of recombinant human insulin-like growth factor I administration on the growth hormone (GH) response to GH-releasing hormone in obesity. J. Clin. Endocrinol. Metab. 86, 167-171 (2001).
Frystyk J, Skjaerbaek C, Vestbo E, Fisker S, Orskov H. Circulating levels of free insulin-like growth factors in obese subjects: the impact of Type 2 diabetes. Diabetes Metab. Res. Rev. 15, 314-322 (1999).
Ricart W, Fernandez-Real JM. No decrease in free IGF-I with increasing insulin in obesity-related insulin resistance. Obes. Res. 9, 631-636 (2001).
Sandhu MS, Gibson JM, Heald AH, Dunger DB, Wareham NJ. Association between insulin-like growth factor-I: insulin-like growth factor-binding protein-1 ratio and metabolic and anthropometric factors in men and women. Cancer Epidemiol. Biomarkers Prev. 13, 166-170 (2004).
Yeagley D, Guo S, Unterman T, Quinn PG. Gene- and activation-specific mechanisms for insulin inhibition of basal and glucocorticoid-induced insulin-like growth factor binding protein-1 and phosphoenolpyruvate carboxykinase transcription. Roles of forkhead and insulin response sequences. J. Biol. Chem. 276, 33705-33710 (2001).
Kok P, Buijs MM, Kok SW et al. Acipimox enhances spontaneous growth hormone secretion in obese women. Am. J. Physiol. Regul. Integr. Comp. Physiol. 286, R693-R698 (2004).
Van Dam EW, Roelfsema F, Helmerhorst FH et al. Low amplitude and disorderly spontaneous growth hormone release in obese women with or without polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 87, 4225-4230 (2002).
Carro E, Senaris R, Considine RV, Casanueva FF, Dieguez C. Regulation of in vivo growth hormone secretion by leptin. Endocrinology 138, 2203-2206 (1997).
Fors H, Matsuoka H, Bosaeus I, Rosberg S, Wikland KA, Bjarnason R. Serum leptin levels correlate with growth hormone secretion and body fat in children. J. Clin. Endocrinol. Metab. 84, 3586-3590 (1999).
Heptulla R, Smitten A, Teague B, Tamborlane WV, Ma YZ, Caprio S. Temporal patterns of circulating leptin levels in lean and obese adolescents: relationships to insulin, growth hormone, and free fatty acids rhythmicity. J. Clin. Endocrinol. Metab. 86, 90-96 (2001).
Ozata M, Ozdemir IC, Licinio J. Human leptin deficiency caused by a missense mutation: multiple endocrine defects, decreased sympathetic tone, and immune system dysfunction indicate new targets for leptin action, greater central than peripheral resistance to the effects of leptin, and spontaneous correction of leptin-mediated defects. J. Clin. Endocrinol. Metab. 84, 3686-3695 (1999).
Ozata M, Dieguez C, Casanueva FF. The inhibition of growth hormone secretion presented in obesity is not mediated by the high leptin levels: a study in human leptin deficiency patients. J. Clin. Endocrinol. Metab. 88, 312-316 (2003).
De Marinis L, Bianchi A, Mancini A et al. Growth hormone secretion and leptin in morbid obesity before and after biliopancreatic diversion: relationships with insulin and body composition. J. Clin. Endocrinol. Metab. 89, 174-180 (2004).
Tschop M, Weyer C, Tataranni PA, Devanarayan V, Ravussin E, Heiman ML. Circulating ghrelin levels are decreased in human obesity. Diabetes 50, 707-709 (2001).
Meyer CW, Korthaus D, Jagia W et al. A novel missense mutation in the mouse growth hormone gene causes semidominant dwarfism, hyperghrelinemia, and obesity. Endocrinology 145, 2531-2541 (2004).
Cummings DE, Clement K, Purnell JQ et al. Elevated plasma ghrelin levels in Prader Willi syndrome. Nat. Med. 8, 643-644 (2002).
Mancini MC, Costa AP, de Melo, ME et al.. Effect of gastric bypass on spontaneous growth hormone and ghrelin release profiles. Obesity (Silver Spring) 14, 383-387 (2006).
Bjorntorp P. Growth hormone, insulin-like growth factor-I and lipid metabolism: interactions with sex steroids. Horm. Res. 46, 188-191 (1996).
Veldhuis JD, Liem AY, South S et al. Differential impact of age, sex steroid hormones, and obesity on basal versus pulsatile growth hormone secretion in men as assessed in an ultrasensitive chemiluminescence assay. J. Clin. Endocrinol. Metab. 80, 3209-3222 (1995).
Hermann M, Berger P. Hormonal changes in aging men: a therapeutic indication? Exp. Gerontol. 36, 1075-1082 (2001).
Molitch ME, Clemmons DR, Malozowski S et al. Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society Clinical Practice Guideline. J. Clin. Endocrinol. Metab. 91, 1621-1634 (2006).
Aimaretti G, Ambrosio MR, Di Somma C et al. Traumatic brain injury and subarachnoid haemorrhage are conditions at high risk for hypopituitarism: screening study at 3 months after the brain injury. Clin. Endocrinol. (Oxford) 61, 320-326 (2004).
Samadani U, Reyes-Moreno I, Buchfelder M. Endocrine dysfunction following traumatic brain injury: mechanisms, pathophysiology and clinical correlations. Acta Neurochir. 93(Suppl.), 121-125 (2005).
Jorgensen JO, Christiansen JS. Clinical aspects of growth hormone deficiency in adults. An overview. Front. Horm. Res. 33, 1-20 (2005).
Merriam GR, Carney C, Smith LC, Kletke M. Adult growth hormone deficiency: current trends in diagnosis and dosing. J. Pediatr. Endocrinol. Metab. 17(Suppl. 4), 1307-1320 (2004).
Mahajan T, Crown A, Checkley S, Farmer A, Lightman S. Atypical depression in growth hormone deficient adults, and the beneficial effects of growth hormone treatment on depression and quality of life. Eur. J. Endocrinol. 151, 325-332 (2004).
Rosen T, Johannsson G, Johansson JO, Bengtsson BA. Consequences of growth hormone deficiency in adults and the benefits and risks of recombinant human growth hormone treatment. A review paper. Horm. Res. 43, 93-99 (1995).
Mukherjee A, Murray RD, Shalet SM. Impact of growth hormone status on body composition and the skeleton. Harm. Res. 62(Suppl. 3), 35-41 (2004).
McCallum RW, Petrie JR, Dominiczak AF, Connell JM. Growth hormone deficiency and vascular risk. Clin. Endocrinol. (Oxford) 57, 11-24 (2002).
Hew FL, O'Neal D, Kamarudin N, Alford FP, Best JD. Growth hormone deficiency and cardiovascular risk. Baillieres Clin. Endocrinol. Metab. 12, 199-216 (1998).
Gola M, Bonadonna S, Doga M, Giustina A. Clinical review: growth hormone and cardiovascular risk factors. J. Clin. Endocrinol. Metab. 90, 1864-1970 (2005).
Rosen T, Bengtsson BA. Premature mortality due to cardiovascular disease in hypopituitarism. Lancet 336, 285-288 (1990).
Miller KK, Biller BM, Lipman JG, Bradwin G, Rifai N, Klibanski A. Truncal adiposity, relative growth hormone deficiency, and cardiovascular risk. Clin. Endocrinol. Metab. 90, 768-774 (2005).
Maison P, Chanson P. Cardiac effects of growth hormone in adults with growth hormone deficiency: a meta-analysis. Circulation 108, 2648-2652 (2003).
Gilchrist FJ, Murray RD, Shalet SM. The effect of long-term untreated growth hormone deficiency (GHD) and 9 years of GH replacement on the quality of life (QoL) of GH-deficient adults. Clin. Endocrinol. (Oxford) 57, 363-370 (2002).
Murray RD, Skillicorn CJ, Howell SJ et al. Influences on quality of life in GH deficient adults and their effect on response to treatment. Clin. Endocrinol. (Oxford) 51, 565-573 (1999).
Abs R, Mattsson AF, Bengtsson BA et al. Isolated growth hormone (GH) deficiency in adult patients: baseline clinical characteristics and responses to GH replacementin comparison with hypopituitary patients. A sub-analysis of the KIMS database. Growth Horm. IGF Res. 15, 349-359 (2005).
Hoybye C. Endocrine and metabolic aspects of adult Prader-Willi syndrome with special emphasis on the effect of growth hormone treatment. Growth Horm. IGF Res. 14, 1-15 (2004).
Maffei P, Munno V, Marshall JD, Scandellari C, Sicolo N. The Alstrom syndrome: is it a rare or unknown disease? Ann. Ital. Med. Int. 17, 221-228 (2002).
Bengtsson BA, Brummer RJ, Bosaeus I. Growth hormone and body composition. Horm. Res. 33(Suppl. 4), 19-24 (1990).
Woodhouse LJ, Mukherjee A, Shalet SM, Ezzat S. The influence of growth hormone status on physical impairments, functional limitations, and health-related quality of life in adults. Endocr. Rev. 27, 287-317 (2006).
Salomon F, Cuneo RC, Hesp R, Sonksen PH. The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency N. Engl. J. Med. 321, 1797-1803 (1989).
Lombardi G, Di Somma C, Rota F, Colao A. Associated hormonal decline in aging: is there a role for GH therapy in aging men? J. Endocrinol. Invest. 28, 99-108 (2005).
Snyder DK, Underwood LE, Clemmons DR. Persistent lipolytic effect of exogenous growth hormone during caloric restriction. Am. J. Med. 98, 129-134 (1995).
Kamel A, Norgren S, Elimam A, Danielsson P, Marcus C. Effects of growth hormone treatment in obese prepubertal boys. J. Clin. Endocrinol. Metab. 85, 1412-1419 (2000).
Albert SG, Mooradian AD. Low-dose recombinant human growth hormone as adjuvant therapy to lifestyle modifications in the management of obesity. J. Clin. Endocrinol. Metab. 89, 695-701 (2004).
Snyder DK, Clemmons DR, Underwood LE. Dietary carbohydrate content determines responsiveness to growth hormone in energy-restricted humans. J. Clin. Endocrinol. Metab. 69, 745-752 (1989).
Thompson JL, Butterfield GE, Gylfadottir UK et al. Effects of human growth hormone, insulin-like growth factor I, and diet and exercise on body composition of obese postmenopausal women. J. Clin. Endocrinol. Metab. 83, 1477-1484 (1998).
Ahn CW, Kim CS, Nam JH et al. Effects of growth hormone on insulin resistance and atherosclerotic risk factors in obese Type 2 diabetic patients with poor glycaemic control. Clin. Endocrinol. (Oxford) 64, 444-449 (2006).
Kim KR, Nam SY, Song YD, Lim SK, Lee HC, Hub KB. Low-dose growth hormone treatment with diet restriction accelerates body fat loss, exerts anabolic effect and improves growth hormone secretory dysfunction in obese adults. Horm. Res. 51, 78-84 (1999).
Nam SY, Kim KR, Cha BS et al. Low-dose growth hormone treatment combined with diet restriction decreases insulin resistance by reducing visceral fat and increasing muscle mass in obese Type 2 diabetic patients. Int. J. Obes. Relat. Metab. Disord. 25, 1101-1107 (2001).
Skaggs SR, Crist DM. Exogenous human growth hormone reduces body fat in obese women. Horm. Res. 35, 19-24 (1991).
Richelsen B, Pedersen SB, Borglum JD, Moller-Pedersen T, Jorgensen J. Jorgensen JO. Growth hormone treatment of obese women for 5 wk: effect on body composition and adipose tissue LPL activity. Am. J Physiol. 266, E211-E216 (1994).
Johannsson G, Marin P, Lonn L et al. Growth hormone treatment of abdominally obese men reduces abdominal fat mass, improves glucose and lipoprotein metabolism, and reduces diastolic blood pressure. J. Clin. Endocrinol. Metab. 82, 727-734 (1997).
Clemmons DR, Snyder DK, Williams R, Underwood LE. Growth hormone administration conserves lean body mass during dietary restriction in obese subjects. J. Clin. Endocrinol. Metab. 64, 878-883 (1987).
Snyder DK, Clemmons DR, Underwood LE. Treatment of obese, diet-restricted subjects with growth hormone for 11 weeks: effects on anabolism, lipolysis, and body composition. J. Clin. Endocrinol. Metab. 67, 54-61 (1988).
Snyder DK, Underwood LE, Clemmons DR. Anabolic effects of growth hormone in obese diet-restricted subjects are dose dependent. Am. J. Clin. Nutr. 52, 431-437 (1990).
Drent ML, Wever LD, Ader HJ, van der Veen EA. Growth hormone administration in addition to a very low calorie diet and an exercise program in obese subjects. Eur. J. Endocrinol. 132, 565-572 (1995).
Tagliaferri M, Scacchi M, Pincelli Al et al. Metabolic effects of biosynthetic growth hormone treatment in severely energy-restricted obese women. Int. J. Obes. Relat. Metab. Disord. 22, 836-841 (1998).
Norrelund H, Borglum J, Jorgensen JO et al. Effects of growth hormone administration on protein dynamics and substrate metabolism during 4 weeks of dietary restriction in obese women. Clin. Endocrinol. (Oxford) 52, 305-312 (2000).
Richelsen B, Pedersen SB, Kristensen K et al. Regulation of lipoprotein lipase and hormone-sensitive lipase activity and gene expression in adipose and muscle tissue by growth hormone treatment during weight loss in obese patients. Metabolism 49, 906-911 (2000).
Sartorio A, Maffiuletti NA, Agosti F, Marinone PG, Ottolini S, Lafortuna CL. Body mass reduction markedly improves muscle performance and body composition in obese females aged 61-75 years: comparison between the effects exerted by energy-restricted diet plus moderate aerobic-strength training alone or associated with rGH or nandrolone undecanoate. Eur. J. Endocrinol. 150, 511-515 (2004).
Herrmann BL, Berg C, Vogel E et al. Effects of a combination of recombinant human growth hormone with metformin on glucose metabolism and body composition in patients with metabolic syndrome. Horm. Metab. Res. 36, 54-61 (2004).
Tomlinson JW, Crabtree N, Clark PM et al. Low-dose growth hormone inhibits 11 β-hydroxysteroid dehydrogenase type 1 but has no effect upon fat mass in patients with simple obesity. J. Clin. Endocrinol. Metab. 88, 2113-2118 (2003).
Franco C, Brandberg J, Lonn L, Andersson B, Bengtsson BA, Johannsson G. Growth hormone treatment reduces abdominal visceral fat in postmenopausal women with abdominal obesity: a 12-month placebo-controlled trial. J. Clin. Endocrinol. Metab. 90, 1466-1474 (2005).
Svensson J, Bengtsson BA, Taskinen MR, Wildund O, Johannsson G. A nine-month, placebo-controlled study of the effects of growth hormone treatment on lipoproteiis and LDL size in abdominally obese men. Growth Horm. IGF Res. 10, 118-126 (2000).
Lucidi P, Parlanti N, Piccioni F, Santeusanio F, De Feo P. Short-term treatment with low doses of recombinant human GH stimulates lipolysis in visceral obese men. J. Clin. Endocrinol. Metab. 87, 3105-3109 (2002).
Fowelin J, Attvall S, Lager I, Bengtsson BA. Effects of treatment with recombinant human growth hormone on insulin sensitivity and glucose metabolism in adults with growth hormone deficiency. Metabolism 42, 1443-1447 (1993).
